Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Camurus
Phase I/II clinical trial initiated for product to treat patients with oral mucositis
November 4th, 2005
Camurus has initiated a phase I/IIa clinical study to evaluate safety, tolerability and preliminary efficacy of CAM2028, an oromucosal formulation of an agent being used for topical treatment of pain in cancer patients with oral mucositis (OM). Mucositis is an inflammation and ulceration of the lining of the mouth, throat or gastrointestinal tract most commonly associated with chemotherapy or radiotherapy for cancer. OM is the most commonly experienced manifestation occurring in around 40% of cancer patients. It is a severe side effect that can limit the patient's ability to tolerate cancer therapy. In more severe cases, mucositis can be extremely painful, preventing...
Source: Biotech Law Weekly (2005-11-04)
|
